Apollomics (APLM)
NASDAQ:APLM
Want to see APLM full AI Analyst Report?
APLM Stock Chart & Stats
$22.52
-$0.28(-2.62%)
At close: 4:00 PM EST
$22.52
-$0.28(-2.62%)
Day’s Range― - ―
52-Week Range$3.66 - $42.12
Previous CloseN/A
Volume6.18K
Average Volume (3M)72.65K
Market Cap
$30.93M
Enterprise Value$12.91M
Total Cash (Recent Filing)$9.77M
Total Debt (Recent Filing)$966.00K
Price to Earnings (P/E)1.2
Beta0.52
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-54.48
Shares Outstanding2,196,052
10 Day Avg. Volume95,090
30 Day Avg. Volume72,653
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-8.48
Price to Sales (P/S)3.18
P/FCF Ratio-2.61
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue65.19
Enterprise Value/Gross Profit65.19
Enterprise Value/Ebitda-0.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-122
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Material Revenue GrowthA large revenue increase in 2025 signals improving commercial or partner traction for Apollomics’ assets. Sustained revenue growth can validate programs, attract non-dilutive partnerships or milestone payments, and reduce future funding reliance if the trend continues over multiple quarters.
Low Reported Debt LoadModest absolute debt keeps interest burden low and preserves flexibility for a development-stage biotech. Lower leverage reduces immediate liquidity drain, making it easier to structure partnership, licensing, or equity raises without being constrained by high mandatory debt service.
Focused Clinical-Stage Oncology PipelineA concentrated portfolio targeting genetically defined cancers aligns with durable structural demand for precision oncology. A clear therapeutic focus improves R&D allocation, makes the company an attractive partner or acquisition target, and can yield high-value regulatory or commercial outcomes if trials succeed.
Bears Say
Persistent Negative Free Cash FlowOngoing negative free cash flow indicates the company cannot self-fund operations or late-stage development. Persistent cash burn requires external financing, increasing dilution or debt issuance risk and creating recurring funding uncertainty for multi-year clinical programs.
Negative Shareholders' EquityNegative equity weakens the balance sheet and heightens financing risk for a loss-making biotech. It can limit access to favorable capital, increase cost of capital, and reduce covenant and counterparty flexibility, making sustained R&D investment and trial completion more challenging.
Deep, Persistent Losses And Weak MarginsLarge operating losses and lack of gross profit despite revenue growth suggest earnings are not yet sustainable. Negative margins constrain reinvestment capacity, increase reliance on external funding, and raise questions about the quality and durability of reported revenue streams over the medium term.
Apollomics News
APLM FAQ
What was Apollomics’s price range in the past 12 months?
Apollomics lowest stock price was $3.66 and its highest was $42.12 in the past 12 months.
What is Apollomics’s market cap?
Apollomics’s market cap is $30.93M.
When is Apollomics’s upcoming earnings report date?
Apollomics’s upcoming earnings report date is Sep 24, 2026 which is in 120 days.
How were Apollomics’s earnings last quarter?
Apollomics released its earnings results on Apr 27, 2026. The company reported $3.795 earnings per share for the quarter, beating the consensus estimate of N/A by $3.795.
Is Apollomics overvalued?
According to Wall Street analysts Apollomics’s price is currently Overvalued.
Does Apollomics pay dividends?
Apollomics does not currently pay dividends.
What is Apollomics’s EPS estimate?
Apollomics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apollomics have?
Apollomics has 2,196,052 shares outstanding.
What happened to Apollomics’s price movement after its last earnings report?
Apollomics reported an EPS of $3.795 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.693%.
Which hedge fund is a major shareholder of Apollomics?
Currently, no hedge funds are holding shares in APLM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apollomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.99%
12-Months-Change
Fundamentals
Return on Equity
288.40%
Trailing 12-Months
Asset Growth
-48.74%
Trailing 12-Months
Company Description
Apollomics
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Technical Analysis
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Exicure
―
CytoMed Therapeutics Limited
―
Ownership Overview
0.61% Insiders
0.03% Mutual Funds
― Other Institutional Investors
99.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---